User menu

Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

Bibliographic reference Delattre, Isabelle ; Taccone, Fabio S. ; Jacobs, Frédérique ; Hites, Maya ; Dugernier, Thierry ; et. al. Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?. In: Expert Review of Anti-infective Therapy, Vol. 15, no.7, p. 677-688 (2017)
Permanent URL http://hdl.handle.net/2078.1/186493
  1. Gonçalves-Pereira Joao, Póvoa Pedro, Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams, 10.1186/cc10441
  2. Pea Federico, Viale Pierluigi, Furlanut Mario, Antimicrobial Therapy in Critically Ill Patients : A Review of Pathophysiological Conditions Responsible for Altered Disposition and Pharmacokinetic Variability, 10.2165/00003088-200544100-00002
  3. Roberts Jason A., Lipman Jeffrey, Pharmacokinetic issues for antibiotics in the critically ill patient : , 10.1097/ccm.0b013e3181961bff
  4. Roberts Jason A., Ulldemolins Marta, Roberts Michael S., McWhinney Brett, Ungerer Jacobus, Paterson David L., Lipman Jeffrey, Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept, 10.1016/j.ijantimicag.2010.06.008
  5. Pea Federico, Viale Pierluigi, Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock – does the dose matter?, 10.1186/cc7774
  6. Pea F., Scudeller L., Lugano M., Baccarani U., Pavan F., Tavio M., Furlanut M., Rocca G. D., Bresadola F., Viale P., Hyperlactacidemia Potentially Due to Linezolid Overexposure in a Liver Transplant Recipient, 10.1086/499533
  7. Scaglione Francesco, Can PK/PD be used in everyday clinical practice, 10.1016/s0924-8579(02)00020-1
  8. Hyatt Judith M., McKinnon Peggy S., Zimmer Gabrial S., Schentag Jerome J., The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome : Focus on Antibacterial Agents, 10.2165/00003088-199528020-00005
  9. Craig William A., State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men, 10.1086/516284
  10. Wong G., Brinkman A., Benefield R. J., Carlier M., De Waele J. J., El Helali N., Frey O., Harbarth S., Huttner A., McWhinney B., Misset B., Pea F., Preisenberger J., Roberts M. S., Robertson T. A., Roehr A., Sime F. B., Taccone F. S., Ungerer J. P. J., Lipman J., Roberts J. A., An international, multicentre survey of  -lactam antibiotic therapeutic drug monitoring practice in intensive care units, 10.1093/jac/dkt523
  11. Craig William A, Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid, 10.1016/s0891-5520(03)00065-5
  12. Roberts Jason A., Kruger Peter, Paterson David L., Lipman Jeffrey, Antibiotic resistance—What’s dosing got to do with it? : , 10.1097/ccm.0b013e318180fe62
  13. Craig William A., Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins, 10.1016/0732-8893(95)00053-d
  14. Zeitlinger M. A., Derendorf H., Mouton J. W., Cars O., Craig W. A., Andes D., Theuretzbacher U., Protein Binding: Do We Ever Learn?, 10.1128/aac.01433-10
  15. Andes D., Craig W.A., Animal model pharmacokinetics and pharmacodynamics: a critical review, 10.1016/s0924-8579(02)00022-5
  16. Sinnollareddy Mahipal G, Roberts Michael S, Lipman Jeffrey, Roberts Jason A, β-Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review, 10.1111/j.1440-1681.2012.05715.x
  17. Muller A. E., Punt N., Mouton J. W., Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia, 10.1093/jac/dks468
  18. MacVane S. H., Kuti J. L., Nicolau D. P., Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia, 10.1128/aac.01463-13
  19. Li C., Du X., Kuti J. L., Nicolau D. P., Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections, 10.1128/aac.00294-06
  20. Rhodes Nathaniel J., Kuti Joseph L., Nicolau David P., Van Wart Scott, Nicasio Anthony M., Liu Jiajun, Lee Benjamin J., Neely Michael N., Scheetz Marc H., Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival, 10.1128/aac.01956-15
  21. Ariano Robert E, Nyhlén Anna, Donnelly J Peter, Sitar Daniel S, Harding Godfrey KM, Zelenitsky Sheryl A, Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia, 10.1345/aph.1e271
  22. McKinnon Peggy S., Paladino Joseph A., Schentag Jerome J., Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections, 10.1016/j.ijantimicag.2007.12.009
  23. Crandon J. L., Bulik C. C., Kuti J. L., Nicolau D. P., Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa, 10.1128/aac.01183-09
  24. Mouton Johan W, Vinks Alexander A, Pharmacokinetic/Pharmacodynamic Modelling of Antibacterials In Vitro and In Vivo Using Bacterial Growth and Kill Kinetics : The Minimum Inhibitory Concentration versus Stationary Concentration, 10.2165/00003088-200544020-00005
  25. Craig WA, Scand J Infect Dis Suppl, 74, 63 (1990)
  26. Manduru M, Antimicrob Agents Chemother, 41, 2053 (1997)
  27. Mouton J W, den Hollander J G, Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model., 10.1128/aac.38.5.931
  28. Tam V. H., Pharmacodynamics of cefepime in patients with Gram-negative infections, 10.1093/jac/dkf130
  29. Tam V. H., Schilling A. N., Neshat S., Poole K., Melnick D. A., Coyle E. A., Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa, 10.1128/aac.49.12.4920-4927.2005
  30. Lee Su Young, Kuti Joseph L., Nicolau David P., Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infections, 10.1016/j.jinf.2006.09.004
  31. Hayashi Yoshiro, Lipman Jeffrey, Udy Andrew A., Ng Mandy, McWhinney Brett, Ungerer Jacobus, Lust Karin, Roberts Jason A., β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia, 10.1016/j.ijantimicag.2012.10.002
  32. Aitken Samuel L., Altshuler Jerry, Guervil David J., Hirsch Elizabeth B., Ostrosky-Zeichner Luis L., Ericsson Charles D., Tam Vincent H., Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia, 10.1016/j.ijantimicag.2014.12.018
  33. Piccoli L., Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion, 10.1093/jac/dkg467
  34. Navas D., Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics, 10.1093/jac/dkh381
  35. Huttner A, J Antimicrob Chemother, 70, 3178 (2015)
  36. Abdul-Aziz Mohd H., Lipman Jeffrey, Akova Murat, Bassetti Matteo, De Waele Jan J., Dimopoulos George, Dulhunty Joel, Kaukonen Kirsi-Maija, Koulenti Despoina, Martin Claude, Montravers Philippe, Rello Jordi, Rhodes Andrew, Starr Therese, Wallis Steven C., Roberts Jason A., Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort, 10.1093/jac/dkv288
  37. Ulldemolins Marta, Martín-Loeches Ignacio, Llauradó-Serra Mireia, Fernández Javier, Vaquer Sergi, Rodríguez Alejandro, Pontes Caridad, Calvo Gonzalo, Torres Antoni, Soy Dolors, Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements, 10.1093/jac/dkv503
  38. Tamme K., Oselin K., Kipper K., Tasa T., Metsvaht T., Karjagin J., Herodes K., Kern H., Starkopf J., Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock, 10.1111/aas.12629
  39. Martínková Jiřina, Malbrain Manu L.N.G., Havel Eduard, Šafránek Petr, Bezouška Jan, Kaška Milan, pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam, 10.5603/ait.a2015.0082
  40. Öbrink-Hansen Kristina, Juul Rasmus Vestergaard, Storgaard Merete, Thomsen Marianne Kragh, Hardlei Tore Forsingdal, Brock Birgitte, Kreilgaard Mads, Gjedsted Jakob, Population Pharmacokinetics of Piperacillin in the Early Phase of Septic Shock: Does Standard Dosing Result in Therapeutic Plasma Concentrations?, 10.1128/aac.01347-15
  41. Awissi Don-Kelena, Beauchamp Annie, Hébert Elisabeth, Lavigne Viviane, Munoz Danya Lucia, Lebrun Geneviève, Savoie Michel, Fagnan Mylène, Amyot Julie, Tétreault Nicolas, Robitaille Robert, Varin France, Lavallée Christian, Pichette Vincent, Leblanc Martine, Pharmacokinetics of an Extended 4-hour Infusion of Piperacillin-Tazobactam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy, 10.1002/phar.1604
  42. Sime Fekade Bruck, Roberts Michael S., Tiong Ing Soo, Gardner Julia H., Lehman Sheila, Peake Sandra L., Hahn Uwe, Warner Morgyn S., Roberts Jason A., Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial, 10.1093/jac/dkv123
  43. Udy Andrew A, Lipman Jeffrey, Jarrett Paul, Klein Kerenaftali, Wallis Steven C, Patel Kashyap, Kirkpatrick Carl, Kruger Peter S, Paterson David L, Roberts Michael S, Roberts Jason A, Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?, 10.1186/s13054-015-0750-y
  44. Akers Kevin S., Niece Krista L., Chung Kevin K., Cannon Jeremy W., Cota Jason M., Murray Clinton K., Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients : , 10.1097/ta.0000000000000191
  45. De Waele J, Minerva Anestesiol, 80, 1302 (2014)
  46. Carlier Mieke, Carrette Sofie, Stove Veronique, Verstraete Alain G., De Waele Jan J., Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course, 10.1016/j.ijantimicag.2014.01.028
  47. Asin-Prieto E., Rodriguez-Gascon A., Troconiz I. F., Soraluce A., Maynar J., Sanchez-Izquierdo J. A., Isla A., Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis, 10.1093/jac/dkt304
  48. Butterfield J. M., Lodise T. P., Beegle S., Rosen J., Farkas J., Pai M. P., Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations, 10.1093/jac/dkt300
  49. Sturm Ashley W., Allen Nichole, Rafferty Kelly D., Fish Douglas N., Toschlog Eric, Newell Mark, Waibel Brett, Pharmacokinetic Analysis of Piperacillin Administered with Tazobactam in Critically Ill, Morbidly Obese Surgical Patients, 10.1002/phar.1324
  50. Carlier Mieke, Carrette Sofie, Roberts Jason A, Stove Veronique, Verstraete Alain, Hoste Eric, Depuydt Pieter, Decruyenaere Johan, Lipman Jeffrey, Wallis Steven C, De Waele Jan J, Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?, 10.1186/cc12705
  51. Felton T. W., Hope W. W., Lomaestro B. M., Butterfield J. M., Kwa A. L., Drusano G. L., Lodise T. P., Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections, 10.1128/aac.00521-12
  52. Roberts Jason A., Kirkpatrick Carl M.J., Roberts Michael S., Dalley Andrew J., Lipman Jeffrey, First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis, 10.1016/j.ijantimicag.2009.10.008
  53. Shea Katherine M, Cheatham S Christian, Smith David W, Wack Matthew F, Sowinski Kevin M, Kays Michael B, Comparative Pharmacodynamics of Intermittent and Prolonged Infusions of Piperacillin/Tazobactam Using Monte Carlo Simulations and Steady-State Pharmacokinetic Data from Hospitalized Patients, 10.1345/aph.1m304
  54. Langgartner J., Lehn N., Glück T., Herzig H., Kees F., Comparison of the Pharmacokinetics of Piperacillin and Sulbactam during Intermittent and Continuous Intravenous Infusion, 10.1159/000107725
  55. Rafati Mohammad Reza, Rouini Mohammad Reza, Mojtahedzadeh Mojtaba, Najafi Atabak, Tavakoli Hassan, Gholami Kheirollah, Fazeli Mohammad Reza, Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients, 10.1016/j.ijantimicag.2006.02.020
  56. Zeitlinger M. A., Erovic B. M., Sauermann R., Georgopoulos A., Müller M., Joukhadar C., Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis, 10.1093/jac/dki284
  57. Georges Bernard, Conil Jean-Marie, Ruiz Stéphanie, Seguin Thierry, Cougot Pierre, Fourcade Olivier, Houin Georges, Saivin Sylvie, Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations : Ceftazidime dosage regimen in intensive care patients, 10.1111/j.1365-2125.2011.04117.x
  58. Georges B., Conil J.-M., Seguin T., Ruiz S., Minville V., Cougot P., Decun J.-F., Gonzalez H., Houin G., Fourcade O., Saivin S., Population Pharmacokinetics of Ceftazidime in Intensive Care Unit Patients: Influence of Glomerular Filtration Rate, Mechanical Ventilation, and Reason for Admission, 10.1128/aac.00430-09
  59. Mouton Johan W., Punt Nieko, Vinks Alexander A., A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit, 10.1016/j.clinthera.2005.06.013
  60. Pea F., Viale P., Damiani D., Pavan F., Cristini F., Fanin R., Furlanut M., Ceftazidime in Acute Myeloid Leukemia Patients with Febrile Neutropenia: Helpfulness of Continuous Intravenous Infusion in Maximizing Pharmacodynamic Exposure, 10.1128/aac.49.8.3550-3553.2005
  61. Cousson J., Floch T., Vernet-Garnier V., Appriou M., Petit J.S., Jovenin N., Lamiable D., Hoizey G., Intérêt pharmacodynamique de la perfusion continue vs l'administration intermittente de ceftazidime dans les pneumonies nosocomiales sévères, 10.1016/j.patbio.2005.06.002
  62. Traunmuller F., Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients, 10.1093/jac/49.1.129
  63. Buijk S. L. C. E., Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections, 10.1093/jac/49.1.121
  64. Hanes Scott D, Wood G.Christopher, Herring Vanessa, Croce Martin A, Fabian Timothy C, Pritchard Elizabeth, Boucher Bradley A, Intermittent and continuous ceftazidime infusion for critically ill trauma patients, 10.1016/s0002-9610(00)00388-3
  65. Angus B. J., Smith M. D., Suputtamongkol Y., Mattie H., Walsh A. L., Wuthiekanun V., Chaowagul W., White N. J., Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusionvsintermittent bolus injection in septicaemic melioidosis, 10.1111/j.1365-2125.2000.00179.x
  66. Carlier Mieke, Taccone Fabio S., Beumier Majorie, Seyler Lucie, Cotton Frédéric, Jacobs Frédérique, Roberts Jason A., Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy, 10.1016/j.ijantimicag.2015.05.020
  67. Sime Fekade Bruck, Roberts Michael S., Tiong Ing Soo, Gardner Julia H., Lehman Sheila, Peake Sandra L., Hahn Uwe, Warner Morgyn S., Roberts Jason A., Adequacy of High-Dose Cefepime Regimen in Febrile Neutropenic Patients with Hematological Malignancies, 10.1128/aac.00389-15
  68. Cheatham S. Christian, Shea Katherine M., Healy Daniel P., Humphrey Melissa L., Fleming Megan R., Wack Matthew F., Smith David W., Sowinski Kevin M., Kays Michael B., Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients, 10.1016/j.ijantimicag.2010.08.016
  69. Chapuis Thomas M, Giannoni Eric, Majcherczyk Paul A, Chioléro René, Schaller Marie-Denise, Berger Mette M, Bolay Saskia, Décosterd Laurent A, Bugnon Denis, Moreillon Philippe, Prospective monitoring of cefepime in intensive care unit adult patients, 10.1186/cc8941
  70. Nicasio A. M., Ariano R. E., Zelenitsky S. A., Kim A., Crandon J. L., Kuti J. L., Nicolau D. P., Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia, 10.1128/aac.01141-08
  71. Roos J. F., Bulitta J., Lipman J., Kirkpatrick C. M. J., Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units, 10.1093/jac/dkl349
  72. Georges B., Conil J.-M., Cougot P., Decun J.-F., Archambaud M., Seguin T., Chabanon G., Virenque C., Houin G., Saivin S., Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen, 10.5414/cpp43360
  73. Lipman Jeffrey, Wallis Steven C., Boots Robert J., Cefepime Versus Cefpirome: The Importance of Creatinine Clearance : , 10.1213/01.ane.0000077077.54084.b0
  74. Malone R. S., Fish D. N., Abraham E., Teitelbaum I., Pharmacokinetics of Cefepime during Continuous Renal Replacement Therapy in Critically Ill Patients, 10.1128/aac.45.11.3148-3155.2001
  75. Mathew Sumith K., Mathew Binu S., Neely Michael N., Naik Girish S., Prabha Ratna, Jacob Gijoe G., K Subramani, Fleming Denise H., A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients : , 10.1097/ftd.0000000000000323
  76. Mattioli Francesca, Fucile Carmen, Del Bono Valerio, Marini Valeria, Parisini Andrea, Molin Alexandre, Zuccoli Maria Laura, Milano Giulia, Danesi Romano, Marchese Anna, Polillo Marialuisa, Viscoli Claudio, Pelosi Paolo, Martelli Antonietta, Di Paolo Antonello, Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients, 10.1007/s00228-016-2053-x
  77. Ulldemolins Marta, Soy Dolors, Llaurado-Serra Mireia, Vaquer Sergi, Castro Pedro, Rodríguez Alejandro H., Pontes Caridad, Calvo Gonzalo, Torres Antoni, Martín-Loeches Ignacio, Meropenem Population Pharmacokinetics in Critically Ill Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements, 10.1128/aac.00712-15
  78. Kawano Shinji, Matsumoto Kazuaki, Hara Ryohei, Kuroda Yuko, Ikawa Kazuro, Morikawa Norifumi, Horino Tetsuya, Hori Seiji, Kizu Junko, Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis, 10.1016/j.jiac.2015.02.011
  79. Pai Manjunath P., Cojutti Piergiorgio, Pea Federico, Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections, 10.1007/s40262-015-0266-2
  80. Jaruratanasirikul Sutep, Thengyai Suriyan, Wongpoowarak Wibul, Wattanavijitkul Thitima, Tangkitwanitjaroen Kanyawisa, Sukarnjanaset Waroonrat, Jullangkoon Monchana, Samaeng Maseetoh, Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem during the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units, 10.1128/aac.04166-14
  81. Ramon-Lopez A., Allen J. M., Thomson A. H., Dheansa B. S., James S. E., Hanlon G. W., Stewart B., Davies J. G., Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations, 10.1093/jac/dku429
  82. Varghese J. M., Jarrett P., Wallis S. C., Boots R. J., Kirkpatrick C. M. J., Lipman J., Roberts J. A., Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?, 10.1093/jac/dku413
  83. Frippiat Frédéric, Musuamba Flora Tshinanu, Seidel Laurence, Albert Adelin, Denooz Raphaël, Charlier Corinne, Van Bambeke Françoise, Wallemacq Pierre, Descy Julie, Lambermont Bernard, Layios Nathalie, Damas Pierre, Moutschen Michel, Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study, 10.1093/jac/dku354
  84. Langan KM, Crit Care Resusc, 16, 190 (2014)
  85. Jaruratanasirikul S, J Med Assoc Thai, 96, 1283 (2013)
  86. Cheatham S. Christian, Fleming Megan R., Healy Daniel P., Chung Eun Kyoung, Shea Katherine M., Humphrey Melissa L., Kays Michael B., Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit : The Journal of Clinical Pharmacology, 10.1002/jcph.196
  87. Jaruratanasirikul Sutep, Limapichat Thanya, Jullangkoon Monchana, Aeinlang Nanchanit, Ingviya Natnicha, Wongpoowarak Wibul, Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia, 10.1016/j.ijantimicag.2011.04.019
  88. Crandon Jared L., Ariano Robert E., Zelenitsky Sheryl A., Nicasio Anthony M., Kuti Joseph L., Nicolau David P., Optimization of meropenem dosage in the critically ill population based on renal function, 10.1007/s00134-010-2105-0
  89. Doh K., Woo H., Hur J., Yim H., Kim J., Chae H., Han S., Yim D.-S., Population pharmacokinetics of meropenem in burn patients, 10.1093/jac/dkq317
  90. Bilgrami I., Roberts J. A., Wallis S. C., Thomas J., Davis J., Fowler S., Goldrick P. B., Lipman J., Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration, 10.1128/aac.01582-09
  91. Isla Arantxazu, Rodríguez-Gascón Alicia, Trocóniz Iñaki F, Bueno Lorea, Solinís María Ángeles, Maynar Javier, Sánchez-Izquierdo José Ángel, Pedraz José Luis, Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy : , 10.2165/00003088-200847030-00003
  92. Krueger Wolfgang A., Neeser Gertraud, Schuster Harald, Schroeder Torsten H., Hoffmann Edgar, Heininger Alexandra, Dieterich Hans-Juergen, Forst Helmuth, Unertl Klaus E., Correlation of Meropenem Plasma Levels with Pharmacodynamic Requirements in Critically Ill Patients Receiving Continuous Veno-Venous Hemofiltration, 10.1159/000074527
  93. Robatel C., Decosterd L. A., Biollaz J., Eckert P., Schaller M. D., Buclin T., Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients, 10.1177/0091270003260286
  94. Kitzes-Cohen Ruth, Farin Dina, Piva Guillermo, De Myttenaere-Bursztein Sylvie Anne, Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients, 10.1016/s0924-8579(01)00474-5
  95. Mohd Hafiz AA, Minerva Anestesiol, 78, 94 (2012)
  96. Wong Gloria, Sime Fekade Bruck, Lipman Jeffrey, Roberts Jason A, How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?, 10.1186/1471-2334-14-288
  97. Taccone Fabio Silvio, Laterre Pierre-François, Dugernier Thierry, Spapen Herbert, Delattre Isabelle, Witebolle Xavier, De Backer Daniel, Layeux Brice, Wallemacq Pierre, Vincent Jean-Louis, Jacobs Frédérique, Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock, 10.1186/cc9091
  98. Delattre Isabelle K., Musuamba Flora T., Jacqmin Philippe, Taccone Fabio S., Laterre Pierre-François, Verbeeck Roger K., Jacobs Frédérique, Wallemacq Pierre, Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin, 10.1016/j.clinbiochem.2012.03.030
  99. Wong G., Briscoe S., Adnan S., McWhinney B., Ungerer J., Lipman J., Roberts J. A., Protein Binding of  -Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations?, 10.1128/aac.00951-13
  100. Roberts J. A., Paul S. K., Akova M., Bassetti M., De Waele J. J., Dimopoulos G., Kaukonen K.-M., Koulenti D., Martin C., Montravers P., Rello J., Rhodes A., Starr T., Wallis S. C., Lipman J., Roberts J. A., Lipman J., Starr T., Wallis S. C., Paul S. K., Margarit Ribas A., De Waele J. J., De Crop L., Spapen H., Wauters J., Dugernier T., Jorens P., Dapper I., De Backer D., Taccone F. S., Rello J., Ruano L., Afonso E., Alvarez-Lerma F., Gracia-Arnillas M. P., Fernandez F., Feijoo N., Bardolet N., Rovira A., Garro P., Colon D., Castillo C., Fernado J., Lopez M. J., Fernandez J. L., Arribas A. M., Teja J. L., Ots E., Carlos Montejo J., Catalan M., Prieto I., Gonzalo G., Galvan B., Blasco M. A., Meyer E., Del Nogal F., Vidaur L., Sebastian R., Garde P. M., Martin Velasco M. d. M., Zaragoza Crespo R., Esperatti M., Torres A., Montravers P., Baldesi O., Dupont H., Mahjoub Y., Lasocki S., Constantin J. M., Payen J. F., Martin C., Albanese J., Malledant Y., Pottecher J., Lefrant J.-Y., Jaber S., Joannes-Boyau O., Orban C., Ostermann M., McKenzie C., Berry W., Smith J., Lei K., Rubulotta F., Gordon A., Brett S., Stotz M., Templeton M., Rhodes A., Ebm C., Moran C., Kaukonen K.-M., Pettila V., Dimopoulos G., Koulenti D., Xristodoulou A., Theodorou V., Kouliatsis G., Sertaridou E., Anthopoulos G., Choutas G., Rantis T., Karatzas S., Balla M., Papanikolaou M., Myrianthefs P., Gavala A., Fildisis G., Koutsoukou A., Kyriakopoulou M., Petrochilou K., Kompoti M., Michalia M., Clouva-Molyvdas F.-M., Gkiokas G., Nikolakopoulos F., Psychogiou V., Malliotakis P., Akoumianaki E., Lilitsis E., Koulouras V., Nakos G., Kalogirou M., Komnos A., Zafeiridis T., Chaintoutis C., Arvaniti K., Matamis D., Chaintoutis C., Kydona C., Gritsi-Gerogianni N., Giasnetsova T., Giannakou M., Soultati I., Chytas I., Antoniadou E., Antipa E., Lathyris D., Koukoubani T., Paraforou T., Spiropoulou K., Bekos V., Spring A., Kalatzi T., Nikolaou H., Laskou M., Strouvalis I., Aloizos S., Kapogiannis S., Soldatou O., Bassetti M., Adembri C., Villa G., Giarratano A., Maurizio Raineri S., Cortegiani A., Montalto F., Strano M. T., Ranieri V. M., Sandroni C., De Pascale G., Molin A., Pelosi P., Montagnani L., Urbino R., Mastromauro I., De Rosa F. G., Ranieri V. M., Cardoso T., Afonso S., Goncalves-Pereira J., Baptista J. P., Akova M., Ozveren A., , DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current  -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?, 10.1093/cid/ciu027
  101. Tam Vincent H., Chang Kai-Tai, Zhou Jian, Ledesma Kimberly R., Phe Kady, Gao Song, Van Bambeke Françoise, Sánchez-Díaz Ana María, Zamorano Laura, Oliver Antonio, Cantón Rafael, Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria, 10.1093/jac/dkx001
  102. Riou Mickaël, Carbonnelle Sylviane, Avrain Laëtitia, Mesaros Narcisa, Pirnay Jean-Paul, Bilocq Florence, De Vos Daniel, Simon Anne, Piérard Denis, Jacobs Frédérique, Dediste Anne, Tulkens Paul M., Van Bambeke Françoise, Glupczynski Youri, In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy, 10.1016/j.ijantimicag.2010.08.005
  103. Bassetti Matteo, Welte Tobias, Wunderink Richard G., Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?, 10.1186/s13054-016-1197-5
  104. Nicolau David P, Pharmacodynamic optimization of β-lactams in the patient care setting, 10.1186/cc6818